Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
PHARMADRUG Aktie jetzt für 0€ handeln | |||||
15.11.24 | Pharmadrug Inc (2): Pharmadrug issues debenture units to replace debentures | 12 | Stockwatch | ||
15.11.24 | PharmaDrug Inc.: PharmaDrug Announces Issuance of Debenture Units | 776 | Newsfile | Toronto, Ontario--(Newsfile Corp. - November 15, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development... ► Artikel lesen | |
31.10.24 | Pharmadrug Inc (2): Pharmadrug to issue $414,523 in debenture units | 1 | Stockwatch | ||
31.10.24 | PharmaDrug Inc.: PharmaDrug Announces Proposed Issuance of Debenture Units | 437 | Newsfile | Toronto, Ontario--(Newsfile Corp. - October 31, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development... ► Artikel lesen | |
31.10.24 | Pharmadrug Inc (2): Pharmadrug completes PD-001 stability study | 2 | Stockwatch | ||
31.10.24 | PharmaDrug Inc.: PharmaDrug's Sairiyo Therapeutics Announces Successful Completion of Stability Study of PD-001 (Patented Reformulated Cepharanthine) to Support Use in Phase 1 Study for Viral Infectious Diseases | 308 | Newsfile | Toronto, Ontario--(Newsfile Corp. - October 31, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development... ► Artikel lesen | |
19.09.24 | PharmaDrug Inc.: PharmaDrug's Sairiyo Therapuetics Announces Initiation of Study Start-Up Activities and Design for Clinical Trial of PD-001 (Patented Reformulated Cepharanthine) for Viral Infectious Diseases | 299 | Newsfile | Toronto, Ontario--(Newsfile Corp. - September 19, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research,... ► Artikel lesen | |
28.08.24 | PharmaDrug Inc.: PharmaDrug's Sairiyo Therapuetics Provides Strategic Plans to Advance PD-001 (Patented Reformulated Cepharanthine) for Viral Infectious Diseases | 463 | Newsfile | Toronto, Ontario--(Newsfile Corp. - August 28, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development... ► Artikel lesen | |
21.08.24 | PharmaDrug Inc.: PharmaDrug's Sairiyo Therapuetics Announces Independent Screening Identifying Cepharanthine's Potential to Bind to Monkeypox (Mpox) Proteins | 506 | Newsfile | Toronto, Ontario--(Newsfile Corp. - August 21, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development... ► Artikel lesen | |
19.08.24 | PharmaDrug Inc.: PharmaDrug's Sairiyo Therapuetics Receives Approval to Initiate Phase 1 Clinical Trial of Patented Reformulated Cepharanthine | 491 | Newsfile | Toronto, Ontario--(Newsfile Corp. - August 19, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development... ► Artikel lesen | |
23.05.24 | PharmaDrug Inc.: Pharmadrug's Securedose Announces LOI with Canadian Controlled Drug Substance Licensed Dealer for Patent Pending Pharmaceutical Grade Cocaine | 349 | Newsfile | Toronto, Ontario--(Newsfile Corp. - May 23, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development... ► Artikel lesen | |
15.05.24 | PharmaDrug Inc.: PharmaDrug's Sairiyo Therapeutics Submits Clinical Trial Application for Phase 1 Study of Patented Reformulated Cepharanthine | 286 | Newsfile |
Toronto, Ontario--(Newsfile Corp. - May 15, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development... ► Artikel lesen | |
13.05.24 | PharmaDrug Inc.: PharmaDrug Provides Forward Plan to Move Its Patent Pending Process and Formulation of Pharmaceutical Grade Biosynthetic Cocaine Through Development into Commercialization | 347 | Newsfile | Toronto, Ontario--(Newsfile Corp. - May 13, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development... ► Artikel lesen | |
02.05.24 | PharmaDrug Inc.: PharmaDrug Announces Director Appointment and Resignation | 774 | Newsfile | Toronto, Ontario--(Newsfile Corp. - May 2, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development... ► Artikel lesen | |
01.05.24 | PharmaDrug Inc.: PharmaDrug's Sairiyo Therapeutics Completes Clinical and Regulatory Package for Phase 1 Study of Patented Reformulated Cepharanthine | 427 | Newsfile | Toronto, Ontario--(Newsfile Corp. - May 1, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development... ► Artikel lesen | |
16.04.24 | PharmaDrug Inc.: PharmaDrug's SecureDose Announces the Advancement of Process Development of Its Biosynthetic Formulation of Pharmaceutical Grade Cocaine | 646 | Newsfile | Toronto, Ontario--(Newsfile Corp. - April 16, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
AURORA CANNABIS | 3,656 | -0,11 % | Aurora Cannabis Aktie: Ein neuer Lichtblick! | Der kanadische Cannabisproduzent positioniert sich durch internationale Markterschließung, technologische Innovation und solide Finanzlage für langfristiges Wachstum. Aurora Cannabis zieht weiterhin... ► Artikel lesen | |
CANOPY GROWTH | 0,845 | -0,24 % | Schock-News für Canopy Growth Anleger vor dem Wochenende: So müssen Sie heute noch auf diese Sondermeldung reagieren! | ||
TILRAY BRANDS | 0,544 | +0,41 % | Is Tilray Brands a Millionaire Maker? | ||
INNOCAN PHARMA | 0,105 | -1,42 % | Innocan Pharma meldet Ergebnisse für das Gesamtjahr 2024: Verdoppelung des Umsatzes auf 29,4 Millionen US$ | Herzliya, Israel und Calgary, Alberta - 31. März 2025 / IRW-Press / Innocan Pharma Corporation (CSE: INNO) (FWB: IP4) (OTC: INNPF) (das
"Unternehmen" oder "Innocan"), ein pharmazeutisches Technologieunternehmen... ► Artikel lesen | |
TAAT GLOBAL ALTERNATIVES | 0,109 | 0,00 % | TAAT Global Alternatives Inc (2): TAAT to release timing of 2024, Q1 2025 filing April 14 | ||
DERMAPHARM | 35,550 | -2,60 % | Dermapharm: Dermapharm bleibt für das Geschäftsjahr 2025 vorsichtig optimistisch; mwb research stuft auf HALTEN | Die Dermapharm Holding SE (DMP) hat robuste Finanzergebnisse für das Geschäftsjahr 2024 vorgelegt: Der Umsatz stieg im Jahresvergleich um 4,0% auf 1.181 Mio. EUR, das bereinigte EBITDA legte um 1,7%... ► Artikel lesen | |
CRONOS GROUP | 1,531 | -2,30 % | Cronos Group Inc.: Cronos Appoints Anna Shlimak as Chief Financial Officer | TORONTO, March 19, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) ("Cronos" or the "Company"), an innovative global cannabinoid company, today announced the appointment of Anna... ► Artikel lesen | |
SYNBIOTIC | 3,020 | -5,62 % | EQS-News: SYNBIOTIC SE: SYNBIOTIC stellt erstmals Medizinalcannabis als Lutschpastille für den deutschen Markt vor | EQS-News: SYNBIOTIC SE
/ Schlagwort(e): Produkteinführung
SYNBIOTIC stellt erstmals Medizinalcannabis als Lutschpastille für den deutschen Markt vor
01.04.2025 / 15:13... ► Artikel lesen | |
VIATRIS | 6,974 | +0,09 % | How Is Viatris' Stock Performance Compared to Other Biotech Stocks? | ||
DIGICANN VENTURES | 0,004 | 0,00 % | Digicann Ventures Inc: Digicann Ventures extends debentures | ||
ORGANIGRAM GLOBAL | 0,875 | -7,33 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 01.04.2025 | Das Instrument 0OG0 CA68620P7056 ORGANIGRAM HLDGS INC. EQUITY wird cum Kapitalmassnahme gehandelt am 01.04.2025 und ex Kapitalmassnahme am 02.04.2025 The instrument 0OG0 CA68620P7056 ORGANIGRAM HLDGS... ► Artikel lesen | |
CRESCO LABS | 0,538 | -1,56 % | Cresco Labs Aktie: Komplexe Lage droht? | Cresco Labs verzeichnete im Geschäftsjahr 2024 eine beeindruckende finanzielle Entwicklung mit einem Jahresumsatz von 724 Millionen Euro. Trotz dieser positiven Kennzahlen schloss das Unternehmen mit... ► Artikel lesen | |
GREEN THUMB INDUSTRIES | 4,664 | +1,92 % | Green Thumb Industries Inc. to Hold First Quarter 2025 Earnings Conference Call on May 7, 2025 | ||
SNDL | 1,243 | -0,40 % | SNDL Inc.: SNDL Reports Fourth Quarter and Full Year 2024 Financial and Operational Results | The Company reports Record Full Year Net Revenue, Gross Profit and Gross Margin, as well as positive Cash Flow and Free Cash Flow
CALGARY, AB, March 18, 2025... ► Artikel lesen | |
MYDECINE INNOVATIONS GROUP | 0,002 | 0,00 % | Aquis Stock Exchange: Withdrawal from Trading - Mydecine Innovations Group Inc. | Aquis Stock Exchange
Aquis Stock Exchange: Withdrawal from Trading 02-Apr-2025 / 07:00 GMT/BST
The issuer is solely responsible for the content of this... ► Artikel lesen |